open access
Recommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemia
Affiliations- Katedra Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków, Polska
- Klinika Krążenia Płucnego i Chorób Zakrzepowo-Zatorowych, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia, Otwock, Polska
- Katedra i Klinika Chorób Wewnętrznych i Diabetologii, Uniwersytet Medyczny w Poznaniu, Szpital im. Fr. Raszei, Poznań, Polska
- Klinika Hematologii i Transpantologii Gdańskiego Uniwersytetu Medycznego, Gdańsk, Polska
- Instytut Hematologii i Transfuzjologii w Warszawie, Polska
open access
Abstract
Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.
Abstract
Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.
Keywords
Chronic myeloid leukemia; Tyrosine kinase inhibitors; Co-morbidities
About this articleTitle
Recommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemia
Journal
Issue
Pages
184-196
Published online
2016-07-01
DOI
10.1016/j.achaem.2016.06.001
Bibliographic record
Acta Haematol Pol 2016;47(3):184-196.
Keywords
Chronic myeloid leukemia
Tyrosine kinase inhibitors
Co-morbidities
Authors
Tomasz Sacha
Sebastian Szmit
Dorota Zozulińska-Ziółkiewicz
Witold Prejzner
Joanna Góra-Tybor